Notice of Extraordinary General Meeting and Proxy Form
Released
Released
Announcement PDF
Notice of Extraordinary General Meeting
Radiopharm Theranostics Limited ACN 647 877 889
1
Notice of Extraordinary General Meeting
Radiopharm Theranostics Limited ACN 647 877 889
Notice is given that the Extraordinary General Meeting of Radiopharm Theranostics Limited ACN 647 877
889 (Company) will be held at:
Location Virtually via the Automic Investor Portal at investor.automic.com.au by following
the instructions contained in this Notice of Meeting
Date Friday 11 September 2026
Time 11:00 am (Melbourne time) Registration from 10:45 am (Melbourne time)
Online meeting details
The Company will hold the Meeting virtually through Automic Investor Portal via
investor.automic.com.au. Shareholders that have an existing account with Automic will be able to watch,
listen and vote online.
Shareholders who do not have an account with Automic are strongly encouraged to register for an
account as soon as possible and well in advance of the Meeting to avoid any delays on the day of
the Meeting.
An account can be created via the following link investor.automic.com.au and then clicking on “register”
and following the prompts. Shareholders will require their holder number (Securityholder Reference
Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.
To access the virtual meeting on the day:
1. Open your internet browser and go to investor.automic.com.au
2. Login with your username and password or click “register” if you haven’t already created an
account. Shareholders are encouraged to create an account prior to the start of the
meeting to ensure there is no delay in attending the virtual meeting.
3. After logging in, a banner will display at the bottom of your screen to indicate that the meeting is
open for registration, click on “Register” when this appears. Alternatively, click on “Meetings”
on the left-hand menu bar to join the meeting.
4. Click on “Join Meeting” and follow the prompts on screen to register and vote.
Shareholders will be able to vote (see the “Voting virtually at the Meeting” section of this Notice of
Meeting below) and ask questions at the virtual meeting.
The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in
respect to the formal items of business as well as general questions in respect to the Company and its
business.
Notice of Extraordinary General Meeting 2
Voting virtually at the Meeting
Shareholders who wish to vote virtually on the day of the EGM can do so by logging into the Automic
shareholder portal.
1. Open your internet browser and go to investor.automic.com.au
2. Login using your username and password. If you do not already have an account, click
“Register” and follow the prompts. Shareholders are encouraged to register prior to the
commencement of the Meeting to avoid delays in accessing the virtual platform.
3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for
registration. Click “Register”. Alternatively, select Meetings from the left-hand menu.
4. Click on “Join Meeting” and follow the prompts.
5. When the Chair of the Meeting declares the poll open, select the “Voting” dropdown menu on
the right-hand side of your screen.
6. Select either the “Full” or “Allocate” option to access your electronic voting card.
7. Follow the prompts to record your voting direction for each resolution and click “Submit votes”.
For allocated votes, the number of votes submitted must not exceed your remaining available
units. Important: Votes cannot be amended once submitted.
For further information on the live voting process please see the Registration and Voting Guide at
https://www.automicgroup.com.au/virtual-EGMs/
It is recommended that Shareholders wishing to attend the Meeting log in from 15 to 30 minutes prior to
the scheduled start time.
If Shareholders are unable to attend the Meeting they are encouraged to return the proxy form to the
Company in accordance with the instructions thereon.
Returning the proxy form will not preclude a Shareholder from attending and voting at the Meeting
should they elect to do so.
If you have any questions regarding attendance at, or submitting questions for, the Meeting, please
contact the Company’s share registry, Automic, by telephone on 1300 288 664 (from within Australia) or
+61 2 9698 5414 (outside of Australia).
Shareholder Questions
Whilst Shareholders will be provided with the opportunity to submit questions online at the Meeting, it
would be desirable if the Company was able to receive them in advance.
Shareholders are therefore requested to send any questions they may have for the Company or its
Directors at the virtual Extraordinary general meeting to the Company Secretary via email
Au.cosec@acclime.com with subject ‘RAD EGM 2026’.
Please note that not all questions may be able to be answered during the Meeting. In this case answers
will be made available on the Company’s website after the Meeting.
Notice of Extraordinary General Meeting 3
Special Business
Resolutions 1(a) and 1(b) – Ratification of prior issue of First Tranche
Placement Shares to Placement Participants and ADS Shares
To consider and, if in favour, to pass the following resolutions as ordinary resolutions:
1 ‘That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify:
(a) the issue of 408,839,531 Placement Shares (First Tranche Placement Shares) issued
on 3 August 2026; and
(b) the issue of 384,493,800 ADS Shares issued on 28 July 2026,
as detailed and on the terms in the Explanatory Memorandum.’
The Directors unanimously recommend you vote in favour of this resolution.
Resolution 2 – Approval to issue Second Tranche Placement Shares to
Placement Participants
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
2 ‘That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the
proposed issuance and allotment of up to 40,000,000 Placement Shares (Second Tranche
Placement Shares) to sophisticated and professional investors under the Placement, as
detailed in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 3 – Approval to issue Placement Attaching Options to Placement
Participants
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
3 ‘That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the
issuance of up to 448,839,531 Placement Attaching Options to sophisticated and professional
investors under the Placement on the terms set out in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolutions 4(a) and 4(b) - Approval to issue SPP Shares and SPP Attaching
Options to Eligible Shareholders
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
4 ‘That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the
issue of:
(a) up to 666,666,667 SPP Shares at the SPP Price per SPP Share (including any
oversubscription up to an aggregate cap of $10 million); and
Notice of Extraordinary General Meeting 4
(b) up to 666,666,667 SPP Attaching Options at an exercise price of $0.018 per SPP
Attaching Option (being one SPP Attaching Option for every one SPP Share issued under
the SPP),
to Eligible Shareholders under the SPP Offer, as detailed and on the terms set out in the
Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 5 – Approval to issue Shortfall Options
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
5 ‘That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the
issuance of up to 200,000,000 Shortfall Options to Trading Capital Management (HK) Ltd on
account of the Shortfall Commitment, as detailed in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 6 – Approval to issue ADR Warrants
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
6 ‘That, for the purpose of Listing Rule 7.1 and for all other purposes, approval is given for the
issue and exercise of up to 1,281,646 Warrants to the US Placement subscribers in connection
with the US Offer on the terms set out in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 7 – Approval to issue Agent Warrants
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
7 ‘That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the
issuance of up to 64,082 Agent Warrants to H.C. Wainwright & Co on account of professional
services provided to the Company, as detailed in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolutions 8(a) to 8(d) – Approval to issue SPP Shares and SPP Attaching
Options to Directors
To consider and, if in favour, to pass the following resolutions as ordinary resolutions:
8 ‘That, for the purposes of Listing Rule 10.11 and for all other purposes, Shareholders approve the
issuance and allotment of:
(a) to Director Paul Hopper: up to 1,666,667 SPP Shares at the SPP Price per SPP Share and
up to 1,666,667 SPP Attaching Options with an exercise price of $0.018 and an expiry of
31 July 2029;
(b) to Director Ian Turner up to 1,666,667 SPP Shares at the SPP Price per SPP Share and up
to 1,666,667 SPP Attaching Options with an exercise price of $0.018 and an expiry of 31
July 2029;
Notice of Extraordinary General Meeting 5
(c) to Director Bruce Goodwin up to 1,666,667 SPP Shares at the SPP Price per SPP Share;
and up to 1,666,667 SPP Attaching Options with an exercise price of $0.018 and an
expiry of 31 July 2029;
(d) to Chief Executive Officer and Director Riccardo Canevari up to 2,333,333 SPP Shares at
the SPP Price per SPP Share, up to 2,333,333 SPP Attaching Options with an exercise
price of $0.018 and an expiry of 31 July 2029,
as detailed in the Explanatory Memorandum.’
The Directors (with the participating Directors abstaining where applicable) unanimously recommend that
you vote in favour of this resolution.
Dated: 13 August 2026
By order of the Board
Amritha Sushil
Joint Company Secretary
Notice of Extraordinary General Meeting 6
Voting Exclusion Statement
Corporations Act
For the purposes of section 224 Corporations Act, the Company will not disregard a vote if:
(a) it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on
the proposed resolution; and
(b) it is not cast on behalf of a related party or associate of a related party of the Company to whom
the resolution would permit a financial benefit to be given or an associate of such a related party.
Listing Rules
In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the
resolution by or on behalf of:
Resolution 1(a) – Ratification of
prior issue of First Tranche
Placement Shares to Placement
Participants
the Placement Participants or any person who participated in the
issue or who is a counterparty to the agreement being provided
and an associate of that person or those persons.
Resolution 1(b) Ratification of
prior issue of ADS Shares to US
Participants
the US Participants or any person who participated in the issue or
who is a counterparty to the agreement being provided and an
associate of that person or those persons.
Resolution 2 – Approval to issue
Second Tranche Placement
Shares to Placement
Participants
the Placement Participants or any person who is expected to
participate in, or who will obtain a material benefit as a result of,
the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities in the Company) or any associate of
their associates.
Resolution 3 – Approval to issue
Placement Attaching Options to
Placement Participants
the Placement Participants or any person who is expected to
participate in, or who will obtain a material benefit as a result of,
the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities in the Company) or any associate of
their associates.
Resolution 4(a) - Approval to
issue SPP Shares to Eligible
Shareholders
the Eligible Shareholders and any person who is expected to
participate in, or who will obtain a material benefit as a result of,
the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities of the Company) or any associate of
their associates.
Resolution 4(b) - Approval to
issue SPP Attaching Options to
Eligible Shareholders
the Eligible Shareholders and any person who is expected to
participate in, or who will obtain a material benefit as a result of,
the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities of the Company) or any associate of
their associates.
Resolution 5 – Approval to issue
Shortfall Options
Trading Capital Management (HK) Ltd A/C Trafalgar Trading and
any person who is expected to participate in, or who will obtain a
material benefit as a result of, the proposed issue (except a
benefit solely by reason of being a holder of ordinary securities in
the Company) or any associate of their associates.
Notice of Extraordinary General Meeting 7
Resolution 6 – Approval to issue
ADR Warrants
any person who is expected to participate in, or who will obtain a
material benefit as a result of, the proposed issue (except a
benefit solely by reason of being a holder of ordinary securities in
the Company) or any associate of their associates.
Resolution 7– Approval to issue
Agent Warrants
H.C. Wainwright & Co. LLC and any person who is expected to
participate in, or who will obtain a material benefit as a result of,
the proposed issue (except a benefit solely by reason of being a
holder of ordinary securities in the Company) or any associate of
their associates.
Resolution 8(a) – Approval to
issue SPP Shares and SPP
Attaching Options to Director,
Mr Paul Hopper under the SPP
Mr Paul Hopper, being the person who is to receive the securities
in question and any other person who will obtain a material
benefit as a result of the issue of the securities (except a benefit
solely by reason of being a holder of ordinary securities in the
entity) and any associates of those persons.
Resolution 8(b) - Approval to
issue SPP Shares and SPP
Attaching Options to Director,
Mr Ian Turner under the SPP
Mr Ian Turner, being the person who is to receive the securities
in question and any other person who will obtain a material
benefit as a result of the issue of the securities (except a benefit
solely by reason of being a holder of ordinary securities in the
entity) and any associates of those persons.
Resolution 8(c) - Approval to
issue SPP Shares and SPP
Attaching Options to Director,
Mr Bruce Goodwin under the
SPP
Mr Bruce Goodwin, being the person who is to receive the
securities in question and any other person who will obtain a
material benefit as a result of the issue of the securities (except a
benefit solely by reason of being a holder of ordinary securities in
the entity) and any associates of those persons.
Resolution 8(d) - Approval to
issue SPP Shares and SPP
Attaching Options to Chief
Executive Officer and Director,
Mr Riccardo Canevari under the
SPP
Mr Riccardo Canevari, being the person who is to receive the
securities in question and any other person who will obtain a
material benefit as a result of the issue of the securities (except a
benefit solely by reason of being a holder of ordinary securities in
the entity) and any associates of those persons.
However, this does not apply to a vote cast in favour of a resolution by:
(a) a person as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with directions given to the proxy or attorney to vote on the resolution in that
way;
(b) the chair of the Meeting as proxy or attorney for a person who is entitled to vote on the
resolution, in accordance with a direction given to the chair to vote on the resolution as the
chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a
beneficiary provided the following conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary is
not excluded from voting, and is not an associate of a person excluded from
voting, on the resolution; and
(ii) the holder votes on the resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
Notice of Extraordinary General Meeting 8
Notes
(a) Terms used in this Notice of Meeting which are defined in the Explanatory Memorandum have
the meaning given to them in the Explanatory Memorandum.
(b) Subject to the Corporations Act, a Shareholder who is entitled to attend and cast a vote at the
Meeting is entitled to appoint a proxy.
(c) The proxy need not be a Shareholder of the Company. A Shareholder who is entitled to cast
two or more votes may appoint two proxies and may specify the proportion or number of
votes each proxy is appointed to exercise.
(d) If you wish to appoint a proxy and are entitled to do so, then complete and return the
attached proxy form to the Company’s share registry Automic Registry Service Limited as
detailed in the attached proxy form.
(e) You can also lodge your proxy online at https://portal.automic.com.au/investor/home which is
also located on the front of the accompanying proxy form. Alternatively, you can scan the QR
code with your mobile device.
(f) To be effective, the proxy must be received at the share registry of the Company no later than
11:00 am (Melbourne time) on 9 September 2026 (48 hours before the commencement of the
meeting).
(g) A corporation may elect to appoint a representative in accordance with the Corporations Act in
which case the Company will require written proof of the representative’s appointment which
must be lodged with or presented to the Company before the meeting.
(h) The Company has determined under regulation 7.11.37 Corporations Regulations that for the
purpose of voting at the meeting or adjourned meeting, securities are taken to be held by
those persons recorded in the Company’s register of Shareholders as at 7.00 pm (Melbourne
time) on 9 September 2026.
(i) If you have any queries, including how to cast your votes, please contact the Company’s
registered office on 03 9824 5254 (within Australia) or +61 3 9824 5254 (outside Australia)
during business hours.
Notice of Extraordinary General Meeting 9
Explanatory Memorandum
This Explanatory Memorandum accompanies the notice of the EGM of the Company to be held at
11:00 am Melbourne time on 11 September 2026 online via the Automic Investor Portal at
https://portal.automic.com.au/investor/home.
The Explanatory Memorandum has been prepared to assist Shareholders in determining how to vote on
the resolutions set out in the Notice of Meeting and is intended to be read in conjunction with the Notice
of Meeting.
Background
1 On 24 July 2026, the Company announced a capital raising by way of a placement with a firm
commitment of raising approximately $6.7 million, a concurrent ~US$4.1 million (approximately
A$5.8 million) US Direct Registration Offering and an SPP to raise up to approximately $6 million,
in aggregate approximately $18.5 million (Capital Raise).
2 The capital raise involves a two-tranche placement issuing up to 448,839,531 Placement Shares
and up to 448,839,531 Placement Attaching Options to institutional and sophisticated investors to
raise $6.7 million before costs (together, the Placement Offer).
3 The capital raise also involves an SPP to issue up to 666,666,667 SPP Shares and up to
666,666,667 SPP Attaching Options to registered Shareholders at the Record Date (Eligible
Shareholders) (together, the SPP Offer).
4 Subject to satisfying the ASX conditions for quotation of securities, the Company intends to apply
for official quotation of the Placement Attaching Options and SPP Attaching Options (together,
the Attaching Options).
5 The issue of the Attaching Options under the Placement Offer and SPP Offer will be conditional
upon the Company obtaining shareholder approval at this Meeting pursuant to Resolutions 3 and
4.
Placement Shares
6 The capital raising involves a two-tranche placement (Placement) of fully paid ordinary shares
(Placement Shares) to sophisticated and professional investors introduced by the Lead
Manager (Placement Participants).
7 The first tranche of the Placement consists of the issuance of 408,839,531 Placement Shares in
the Company (First Tranche Placement Shares) at an issue price of $0.015 per Share
(Placement Price). The First Tranche Placement Shares were issued and allotted to the
Placement Participants on 3 August 2026.
8 Subject to Shareholder approval at the EGM, the second tranche of the Placement is proposed to
consist of the issuance of up to 40,000,000 Placement Shares at the Placement Price (Second
Tranche Placement Shares).
9 If the issue of the Second Tranche Placement Shares is approved by Shareholders, it is
anticipated that the Second Tranche Placement Shares will be issued and allotted to the
Placement Participants on or about 17 September 2026.
Notice of Extraordinary General Meeting 10
Placement Attaching Options
10 Under the Placement, Placement Participants are anticipated to receive one free attaching option
(Placement Attaching Options) for every new share subscribed for under the Placement, with
an aggregate of approximately 448,839,531 Placement Attaching Options to be issued.
11 The Placement Attaching Options will have an exercise price of $0.018 per Option with an
expiration of 31 July 2029 and are subject to Shareholder approval. It is intended that the
Placement Attaching Options will be quoted on the ASX, subject to meeting all requirements
under ASX Listing Rule 2.5 condition 6. The terms of the Placement Attaching Options are
otherwise set out in Schedule 1 to this Notice of Meeting.
SPP Shares
12 Subject to Shareholder approval at the EGM, the Company proposes to issue to Eligible
Shareholders up to 666,666,667 Shares (SPP Shares) at an issue price, being the lower of:
(a) $0.015; or
(b) 2.5% discount to the VWAP of shares traded on the ASX during the five trading days
prior to 10 September 2026, being the Closing Date,
(being the SPP Price).
13 Subject to Shareholder approval at the EGM, notwithstanding the target raise amount up to
approximately $6 million for the SPP Offer, the Company reserves the right to increase or
decrease the amount to be raised under the SPP Offer to a maximum of $10 million, with an
aggregate of up to 666,666,667 SPP Shares to be issued.
SPP Options
14 Subject to Shareholder approval at the EGM, the Company proposes to issue Eligible
Shareholders one attaching listed Option (SPP Attaching Option) for every SPP Share
subscribed for and issued under the SPP Offer, with an aggregate of up to 666,666,667 SPP
Attaching Options to be issued.
15 The SPP Attaching Options will have an exercise price of $0.018 per SPP Attaching Option,
expiring on 31 July 2029. The terms of the SPP Attaching Option are otherwise set out in
Schedule 1 of this Notice of Meeting.
Shortfall Options
16 Subject to Shareholder approval at the EGM, the Company proposes to issue 200,000,000 options
to Trading Capital Management (HK) Ltd A/C Trafalgar Trading (Shortfall Options) in relation
to its commitment to apply for up to 200,000,000 Shares in the Company under the SPP
(Shortfall Commitment).
17 The Shortfall Options will have an exercise price of $0.018, expiring on 31 July 2029. The
Shortfall Options will have comparable terms to those of the Attaching Options as set out in
Schedule 1 of this Notice.
US Offer
18 The Company has also undertaken a concurrent US$4.1 million (approximately $5.8 million)
direct registered offering in the United States of 1,281,646 American Depositary Shares (ADS),
Notice of Extraordinary General Meeting 11
representing 384,493,800 underlying Shares (ADS Shares) in the Company as detailed in the
Company’s announcement dated 24 July 2026.
19 In place of Attaching Options and subject to Shareholder approval, US subscribers who
subscribed for ADS will receive one warrant for every one ADS subscribed for under the US direct
registration offering (ADR Warrants). Each ADR Warrant will have an exercise price of US$3.79
per ADS, expiring on 31 July 2029 and be subject to shareholder approval at the EGM. (together,
the US Offer).
20 The ADR Warrants will not be quoted.
Agent Warrants
21 Subject to Shareholder approval at the EGM, the Company proposes to issue 64,082 warrants to
H.C. Wainwright & Co. LLC as agent to the Capital Raise (Agent Warrants).
22 The Agent Warrants will have an exercise price of US$3.95, expiring on 31 July 2029. The Agent
Warrants will have comparable terms to those set out in Schedule 1 of this Notice.
23 The Agent Warrants will not be quoted.
Resolutions 1(a) and (b): Ratification of prior issue of First Tranche
Placement Shares to Placement Participants and ADS Shares
The purpose of Resolutions 1(a) and 1(b) is for Shareholders to ratify, under ASX Listing Rule 7.4, and for
all other purposes, the previous issue and allotment of the 408,839,531 First Tranche Placement Shares
to Placement Participants and 384,493,800 ADS Shares on the terms set out herein.
ASX Listing Rule 7.1 and 7.1A
24 Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 limits the amount
of equity securities that a listed company can issue without the approval of its shareholder over
any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of
that 12-month period.
25 Under Listing Rule 7.1A, an eligible entity can seek approval from its members, by way of a
special resolution passed at its annual general meeting, to increase this 15% limit by an extra
10% to 25%. Relevant to shares the subject of this Resolution, Shareholders approved the
additional 10% capacity under Listing Rule 7.1A at the Company’s annual general meeting on 20
November 2025.
26 Given, the issue of the First Tranche Placement Shares and ADS Shares do not fall under any of
the relevant exemptions set out in ASX Listing Rule 7.2 and as it has not yet been approved by
Shareholders, it utilises 442,876,192 of the Company’s 15% capacity under ASX Listing Rule 7.1,
and 350,457,139 of the Company’s 10% capacity under ASX Listing Rule 7.1A, reducing the
Company’s capacity to issue further Equity Securities without Shareholder approval for the 12-
month period following the issue of the First Tranche Placement Shares.
ASX Listing Rule 7.4
27 ASX Listing Rule 7.4 provides that the shareholders of a listed company may approve an issue of
equity securities after it has been made or agreed to be made. If they do, the issue will be
treated as having been made with approval for the purpose of ASX Listing Rule 7.1, thereby
replenishing the Company’s capacity, enabling it to issue further securities up to that limit without
shareholder approval.
Notice of Extraordinary General Meeting 12
28 The Company wishes to retain as much flexibility as possible to issue additional Equity Securities
into the future without having to obtain shareholder approval for such issuance under ASX Listing
Rule 7.1. Accordingly, the Company is seeking Shareholders’ ratification pursuant to ASX Listing
Rule 7.4 for the issue of the First Tranche Placement Shares.
29 Resolutions 1(a) and 1(b) seek Shareholder ratification pursuant to ASX Listing Rule 7.4 for the
issue of the First Tranche Placement Shares and ADS Shares.
Technical information required by ASX Listing Rule 14.1A
30 If Resolution 1(a) and Resolution 1(b) are passed, Shareholder will have ratified the issue of the
Placement Shares and ADS Shares, and the issue of the Placement Shares and ADS Shares will
no longer utilise a portion of the Company’s 15% placement capacity under ASX Listing Rule 7.1
or a portion of the Company’s 10% placement capacity under ASX Listing Rule 7.1A, meaning
that the Company will have an increased ability to issue Equity Securities over the next 12
months without seeking Shareholder approval.
31 If Shareholders do not approve Resolution 1(a) and Resolution 1(b), the Company’s ability to
raise additional equity funds over the next 12 months without Shareholder approval will be
restricted.
Technical information required by ASX Listing Rule 7.5
32 Pursuant to and in accordance with the requirements of ASX Listing Rule 7.5, the following
information is provided in relation to Resolution 1(a) and Resolution 1(b):
(a) the First Tranche Placement Shares, being 408,839,531 fully paid ordinary shares, have
been issued to the Placement Participants, sophisticated and professional investors which
have been identified and introduced by the Lead Manager in Australia and the Placement
Agent in the US (none of which are Material Persons), pursuant to the terms of the
Placement;
(b) the ADS Shares, being 1,281,646 ADS, representing 384,493,800 ordinary shares in the
Company, have been issued to the Placement Participants, sophisticated and professional
investors which have been identified and introduced by the Lead Manager in Australia
and the Placement Agent in the US (none of which are Material Persons), pursuant to the
terms of the US Offer;
(c) the First Tranche Placement Shares were issued on or about 3 August 2026;
(d) the ADS Shares were issued on or about 28 July 2026;
(e) the material terms of the Placement have been summarised in paragraphs 6 to 11 above
and in the Company’s ASX announcement dated 24 July 2026;
(
Share your feedback
Discover